Cargando…

Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules

Hypertension is a diverse illness interlinked with cerebral, cardiovascular (CVS) and renal abnormalities. Presently, the malady is being treated by focusing on Renin- angiotensin system (RAS), voltage-gated calcium channels, peripheral vasodilators, renal and sympathetic nervous systems. Cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramya, Krishnappa, Suresh, Ramalingam, Kumar, Honnavalli Yogish, Kumar, B.R. Prashantha, Murthy, N.B. Sridhara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112834/
https://www.ncbi.nlm.nih.gov/pubmed/32247750
http://dx.doi.org/10.1016/j.bmc.2020.115466
_version_ 1783513553170333696
author Ramya, Krishnappa
Suresh, Ramalingam
Kumar, Honnavalli Yogish
Kumar, B.R. Prashantha
Murthy, N.B. Sridhara
author_facet Ramya, Krishnappa
Suresh, Ramalingam
Kumar, Honnavalli Yogish
Kumar, B.R. Prashantha
Murthy, N.B. Sridhara
author_sort Ramya, Krishnappa
collection PubMed
description Hypertension is a diverse illness interlinked with cerebral, cardiovascular (CVS) and renal abnormalities. Presently, the malady is being treated by focusing on Renin- angiotensin system (RAS), voltage-gated calcium channels, peripheral vasodilators, renal and sympathetic nervous systems. Cardiovascular and renal abnormalities are associated with the overactivation of RAS, which can be constrained by angiotensin- converting enzyme inhibitors (ACEIs), angiotensin II (Ang-II) -AT1 receptor blockers (ARBs) and renin inhibitors. The latter is a new player in the old system. The renin catalyzes the conversion of angiotensinogen to Angiotensin I (Ang-I). This can be overcome by inhibiting renin, a preliminary step, eventually hinders the occurrence of the cascade of events in the RAS. Various peptidomimetics, the first-generation renin inhibitors developed six decades ago have limited drug-like properties as they suffered from poor intestinal absorption, high liver first-pass metabolism and low oral bioavailability. The development of chemically diverse molecules from peptides to nonpeptides expanded the horizon to achieving direct renin inhibition. Aliskiren, a blockbuster drug that emerged as a clinical candidate and got approved by the US FDA in 2007 was developed by molecular modeling studies. Aliskiren indicated superior to average efficacy and with minor adverse effects relative to other RAS inhibitors. However, its therapeutic use is limited by poor oral bioavailability of less than 2% that is similar to first-generation peptidic compounds. In this review, we present the development of direct renin inhibitors (DRIs) from peptidic to nonpeptidics that lead to the birth of aliskiren, its place in the treatment of cardiovascular diseases and its limitations.
format Online
Article
Text
id pubmed-7112834
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71128342020-04-02 Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules Ramya, Krishnappa Suresh, Ramalingam Kumar, Honnavalli Yogish Kumar, B.R. Prashantha Murthy, N.B. Sridhara Bioorg Med Chem Article Hypertension is a diverse illness interlinked with cerebral, cardiovascular (CVS) and renal abnormalities. Presently, the malady is being treated by focusing on Renin- angiotensin system (RAS), voltage-gated calcium channels, peripheral vasodilators, renal and sympathetic nervous systems. Cardiovascular and renal abnormalities are associated with the overactivation of RAS, which can be constrained by angiotensin- converting enzyme inhibitors (ACEIs), angiotensin II (Ang-II) -AT1 receptor blockers (ARBs) and renin inhibitors. The latter is a new player in the old system. The renin catalyzes the conversion of angiotensinogen to Angiotensin I (Ang-I). This can be overcome by inhibiting renin, a preliminary step, eventually hinders the occurrence of the cascade of events in the RAS. Various peptidomimetics, the first-generation renin inhibitors developed six decades ago have limited drug-like properties as they suffered from poor intestinal absorption, high liver first-pass metabolism and low oral bioavailability. The development of chemically diverse molecules from peptides to nonpeptides expanded the horizon to achieving direct renin inhibition. Aliskiren, a blockbuster drug that emerged as a clinical candidate and got approved by the US FDA in 2007 was developed by molecular modeling studies. Aliskiren indicated superior to average efficacy and with minor adverse effects relative to other RAS inhibitors. However, its therapeutic use is limited by poor oral bioavailability of less than 2% that is similar to first-generation peptidic compounds. In this review, we present the development of direct renin inhibitors (DRIs) from peptidic to nonpeptidics that lead to the birth of aliskiren, its place in the treatment of cardiovascular diseases and its limitations. Elsevier Ltd. 2020-05-15 2020-03-28 /pmc/articles/PMC7112834/ /pubmed/32247750 http://dx.doi.org/10.1016/j.bmc.2020.115466 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ramya, Krishnappa
Suresh, Ramalingam
Kumar, Honnavalli Yogish
Kumar, B.R. Prashantha
Murthy, N.B. Sridhara
Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules
title Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules
title_full Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules
title_fullStr Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules
title_full_unstemmed Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules
title_short Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules
title_sort decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. a fleeting look at the old and the promising new molecules
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112834/
https://www.ncbi.nlm.nih.gov/pubmed/32247750
http://dx.doi.org/10.1016/j.bmc.2020.115466
work_keys_str_mv AT ramyakrishnappa decadesoldrenininhibitorsarestillstrugglingtofindanicheinantihypertensivetherapyafleetinglookattheoldandthepromisingnewmolecules
AT sureshramalingam decadesoldrenininhibitorsarestillstrugglingtofindanicheinantihypertensivetherapyafleetinglookattheoldandthepromisingnewmolecules
AT kumarhonnavalliyogish decadesoldrenininhibitorsarestillstrugglingtofindanicheinantihypertensivetherapyafleetinglookattheoldandthepromisingnewmolecules
AT kumarbrprashantha decadesoldrenininhibitorsarestillstrugglingtofindanicheinantihypertensivetherapyafleetinglookattheoldandthepromisingnewmolecules
AT murthynbsridhara decadesoldrenininhibitorsarestillstrugglingtofindanicheinantihypertensivetherapyafleetinglookattheoldandthepromisingnewmolecules